Zealand Pharma A/S reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported sales was DKK 43.71 million compared to DKK 54.19 million a year ago. Net loss was DKK 148.34 million compared to DKK 198.89 million a year ago. Basic loss per share from continuing operations was DKK 3.29 compared to DKK 3.28 a year ago. Diluted loss per share from continuing operations was DKK 3.29 compared to DKK 3.28 a year ago. Basic loss per share was DKK 3.21 compared to DKK 4.61 a year ago. Diluted loss per share was DKK 3.21 compared to DKK 4.61 a year ago.
For the nine months, sales was DKK 80.06 million compared to DKK 95.11 million a year ago. Net loss was DKK 859.69 million compared to DKK 737.89 million a year ago. Basic loss per share from continuing operations was DKK 14.46 compared to DKK 12.73 a year ago. Diluted loss per share from continuing operations was DKK 14.46 compared to DKK 12.73 a year ago. Basic loss per share was DKK 19.28 compared to DKK 17.26 a year ago. Diluted loss per share was DKK 19.28 compared to DKK 17.26 a year ago.